Establishment Labs raises $50M via private placement; Q4 rev. $31.4-$31.8M in-line

unaudited financial results for the fourth quarter and fiscal year 2023. Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be in the range of $31.4 million to $31.8 million, in line with the guidance provided on November 7 in the third quarter earnings release. Based on the expected range for fourth quarter preliminary unaudited

In connection with the Private Placement, the Company entered into a registration rights agreement, dated January 9, 2024 (the “Registration Rights Agreement”), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 (or a prospectus supplement to the Company’s Form S-3 (File No. 333-271418)) to register for resale the Shares and the Common Shares issuable upon the exercise of the Pre-Funded Warrants within 30 calendar days of the closing of the Private Placement, and (ii) use commercially reasonable efforts to have the registration statement declared effective, if not automatically effective upon filing, as soon as reasonably practicable after such registration statement has been filed with the SEC.

On January 9, 2024, Establishment Labs Holdings Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with select institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 1,101,565 common shares (the “Shares”) of the Company, no par value per share (the “Common Shares”), and (ii) in lieu of Common Shares, pre-funded warrants providing for the purchase, upon exercise, of an aggregate of 898,435 Common Shares (the “Pre-Funded Warrants”).